Mechanisms of camptothecin resistance by human topoisomerase I mutations.

[1]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[2]  R. Hertzberg,et al.  On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. , 1989, Biochemistry.

[3]  Eric Patterson,et al.  Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites , 1991, Nucleic Acids Res..

[4]  P. Kraulis.  A program to produce both detailed and schematic plots of protein structures , 1991 .

[5]  N. Saijo,et al.  Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. , 1992, Biochemical and biophysical research communications.

[6]  Y. Pommier,et al.  Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. , 1992, Cancer research.

[7]  J. Wang,et al.  Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. , 1993, Cancer research.

[8]  Y. Pommier,et al.  Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. , 1993, The Journal of biological chemistry.

[9]  Axel T. Brunger,et al.  Assessment of Phase Accuracy by Cross Validation: the Free R Value. Methods and Applications , 1993 .

[10]  D. Kufe,et al.  Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. , 1994, The Journal of biological chemistry.

[11]  H. Nash,et al.  A novel suicide substrate for DNA topoisomerases and site-specific recombinases. , 1995, Nucleic acids research.

[12]  Y. Pommier,et al.  Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. , 1995, Cancer research.

[13]  G. Ireton,et al.  The Domain Organization of Human Topoisomerase I (*) , 1996, The Journal of Biological Chemistry.

[14]  G. Ireton,et al.  Biochemical and Biophysical Analyses of Recombinant Forms of Human Topoisomerase I (*) , 1996, The Journal of Biological Chemistry.

[15]  E A Merritt,et al.  Raster3D: photorealistic molecular graphics. , 1997, Methods in enzymology.

[16]  L. Liu,et al.  Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis. , 1997, Biochemical pharmacology.

[17]  P. Pantazis,et al.  Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning. , 1997, Cancer research.

[18]  W G Hol,et al.  A model for the mechanism of human topoisomerase I. , 1998, Science.

[19]  J. Champoux,et al.  Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. , 1998, Science.

[20]  J. Champoux,et al.  Structural flexibility in human topoisomerase I revealed in multiple non-isomorphous crystal structures. , 1999, Journal of molecular biology.

[21]  M. Bjornsti,et al.  Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity. , 1999, Molecular pharmacology.

[22]  E. Rubin,et al.  The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles. , 1999, Biochemistry.

[23]  Y. Pommier,et al.  Induction of Reversible Complexes between Eukaryotic DNA Topoisomerase I and DNA-containing Oxidative Base Damages , 1999, The Journal of Biological Chemistry.

[24]  R M Esnouf,et al.  Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. , 1999, Acta crystallographica. Section D, Biological crystallography.

[25]  Yves Pommier,et al.  Topoisomerase I inhibitors: selectivity and cellular resistance. , 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[26]  Y. Pommier,et al.  Substitutions of Asn-726 in the Active Site of Yeast DNA Topoisomerase I Define Novel Mechanisms of Stabilizing the Covalent Enzyme-DNA Intermediate* , 2000, The Journal of Biological Chemistry.

[27]  J. Champoux,et al.  Novel insights into catalytic mechanism from a crystal structure of human topoisomerase I in complex with DNA. , 2000, Biochemistry.

[28]  M. Gore,et al.  Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Y. Pommier,et al.  Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. , 2001, Cancer research.

[30]  Y. Pommier,et al.  Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site. , 2001, Cancer research.

[31]  U. Vanhoefer,et al.  Irinotecan in the treatment of colorectal cancer: clinical overview. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Champoux.  DNA topoisomerases: structure, function, and mechanism. , 2001, Annual review of biochemistry.

[33]  Y. Pommier,et al.  Topoisomerase I-mediated DNA damage. , 2001, Advances in cancer research.

[34]  J Navaza,et al.  Implementation of molecular replacement in AMoRe. , 2001, Acta crystallographica. Section D, Biological crystallography.

[35]  A. Burgin,et al.  Synthesis and use of DNA containing a 5'-bridging phosphorothioate as a suicide substrate for type I DNA topoisomerases. , 2001, Methods in molecular biology.

[36]  C. Bailly,et al.  Active Site Mutations in DNA Topoisomerase I Distinguish the Cytotoxic Activities of Camptothecin and the Indolocarbazole, Rebeccamycin* , 2002, The Journal of Biological Chemistry.

[37]  Jang-Yang Chang,et al.  Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. , 2002, Cancer research.

[38]  Y. Pommier,et al.  8-Oxoguanine rearranges the active site of human topoisomerase I , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Lance Stewart,et al.  The mechanism of topoisomerase I poisoning by a camptothecin analog , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Giovanni Chillemi,et al.  Single Mutation in the Linker Domain Confers Protein Flexibility and Camptothecin Resistance to Human Topoisomerase I* , 2003, Journal of Biological Chemistry.

[41]  M. Bjornsti,et al.  Locking the DNA topoisomerase I protein clamp inhibits DNA rotation and induces cell lethality , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[42]  E. Rubin,et al.  Mechanisms of resistance to topoisomerase I-targeting drugs , 2003, Oncogene.

[43]  Y. Pommier,et al.  Structural Impact of the Leukemia Drug 1-β-d-Arabinofuranosylcytosine (Ara-C) on the Covalent Human Topoisomerase I-DNA Complex* , 2003, The Journal of Biological Chemistry.

[44]  J. Champoux,et al.  DNA relaxation by human topoisomerase I occurs in the closed clamp conformation of the protein , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Champoux,et al.  The Role of Lysine 532 in the Catalytic Mechanism of Human Topoisomerase I* , 2004, Journal of Biological Chemistry.